ArticleJournal of hepatocellular carcinoma2026
TACE Combined with Ralox-HAIC (Oxaliplatin Puls Raltitrexed) and System Therapy in Patients with Unresectable Hepatocellular Carcinoma.
Article in Journal of hepatocellular carcinoma, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To retrospective analysis the efficacy and safety of Transarterial Chemoembolization (TACE) combined with Hepatic Arterial Infusion Chemotherapy (Ralox-HAIC, Oxaliplatin + Raltitrexed) and systemic therapy in patients with unresectable Hepatocellular Carcinoma (uHCC). Methods: Clinical data of patients with uHCC who received TACE combined with Ralox-HAIC followed by sequential systemic therapy at our hospital between January 2023 and December 2024 were analyzed. The primary endpoint was Objective Response Rate (ORR). Secondary endpoints included Progression-Free Survival (PFS), Overall Survival (OS) and treatment safety. Results: A total of thirty-six patients with complete data were included. Efficacy evaluation showed: Complete Response (CR) in 6 cases (16.67%), Partial Response (PR) in 22 cases (61.11%), Stable Disease (SD) in 5 cases (13.89%), and Progressive Disease (PD) in 2 cases (5.56%). The ORR was 77.78%, and the Disease Control Rate (DCR) was 91.67%. The median PFS was 12.0 months, and the median OS was 19.0months. The one-year and two-year survival rates were 89% and 38%, respectively. No Grade 4 treatment-related adverse events or treatment-related deaths occurred. Conclusion: TACE combined with Ralox-HAIC and systemic therapy demonstrated a high ORR and DCR with manageable safety in uHCC, warranting further prospective studies for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.